At a Glance
- Status: Active Consortium
- Year Launched: 2013
- Initiating Organization: Alzheimer's Research UK
- Initiator Type: Nonprofit foundation
- Disease focus:
- Location: International
Neurodegenerative diseases that cause dementia are our biggest medical challenge. Dementia affects 820,000 people in the United Kingdom (UK) today and nearly 40 million worldwide. As populations age, the worldwide prevalence of dementia is expected to double every 20 years. Millions of lives will be blighted by these diseases. As well as the enormous social cost, neurodegenerative disease carries an enormous economic impact. In the UK alone, dementia has an economic cost of £23 billion, which is greater than heart disease and cancer combined. The Dementia Consortium focuses on fast-tracking new treatments to find an answer to the neurodegenerative diseases that cause dementia.
The Dementia Consortium aims to expedite the development of new drugs for dementia by supporting research into novel targets for neurodegeneration. It brings together the voluntary, academic, and private sectors to tackle the growing dementia problem. The consortium seeks to end the 10-year wait for a new dementia treatment by closing the gap between fundamental academic research and the pharmaceutical industry’s drug discovery programs. It provides funding, expertise, and resources to support new drug targets emerging from academic research that hold the promise of patient benefit.
Sponsors & Partners
Alzheimer’s Research UK